Table 3.
Base-case probabilistic results over a 30-day time horizon
| Base-case probabilistic results | Without CytoSorb® | With CytoSorb® |
|---|---|---|
| Cohort 1 (comparator: no physiologic clearance) | ||
| Cost (£) | 16,874 | 12,933 |
| Incremental cost (£) | − 3941 | |
| QALYs | 0.06091 | 0.06201 |
| Incremental QALYs | 0.0011 | |
| ICER (£; ∆Cost/∆QALYs) | Dominant | |
| Probability of being cost-effective with £20,000 WTP thresholds (%) | 99.68 | |
| Probability of being cost saving (%) | 99.63 | |
| Cohort 2 (comparator: physiologic clearance) | ||
| Cost (£) | 12,959 | 12,912 |
| Incremental cost (£) | − 47.00 | |
| QALYs | 0.06234 | 0.06250 |
| Incremental QALYs | 0.00017 | |
| ICER (£; ∆Cost/∆QALYs) | Dominant | |
| Probability of being cost-effective with £20,000 WTP thresholds (%) | 53.11 | |
| Probability of being cost saving (%) | 51.06 | |
| Cohort 2 (comparator: physiologic clearance + short-acting antiplatelet) | ||
| Cost (£) | 13,200 | 12,939 |
| Incremental cost (£) | − 261.00 | |
| QALYs | 0.06247 | 0.06249 |
| Incremental QALYs | 0.000013 | |
| ICER (£; ∆Cost/∆QALYs) | Dominant | |
| Probability of being cost-effective with £20,000 WTP thresholds (%) | 77.20 | |
| Probability of being cost saving (%) | 77.02 | |
| Cohort 2 (comparator: physiologic clearance + LMWH) | ||
| Cost (£) | 13,030 | 12,954 |
| Incremental cost (£) | − 77 | |
| QALYs | 0.06248 | 0.06249 |
| Incremental QALYs | 0.000014 | |
| ICER (£; ∆Cost/∆QALYs) | Dominant | |
| Probability of being cost-effective with £20,000 WTP thresholds (%) | 57.06 | |
| Probability of being cost saving (%) | 56.91 | |
QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio, WTP willingness to pay, LMWH low-molecular-weight heparin